Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lurasidone Clear all
Withdrawn No phase listed Observational

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

NCT06328140
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions
Lurasidone, FDA Approved antidepressant treatment
Drug
Lead sponsor
George West Mental Health Foundation d/b/a Skyland Trail
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Major Depressive Disorder With Mixed Features - Extension

NCT01423253
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Garden Grove, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 20, 2026, 1:34 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

NCT01358357
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Dothan, Alabama • Glendale, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

PEARL Schizophrenia Maintenance

NCT01435928
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Matching Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Springdale, Arizona • Little Rock, Arkansas • Cerritos, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

NCT01284517
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Costa Mesa, California • Riverside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

Lithium Drug-Drug Interaction Study With Lurasidone HCl

NCT01074073
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

NCT00790192
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Quetiapine XR, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 20, 2026, 1:34 AM EDT
Not listed Not applicable Interventional

Antidepressant Discontinuation in Treatment Resistant Depression

NCT03786614
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Discontinuation of serotonergic antidepressants, Continuation of serotonergic medications
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 20, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

NCT05741502
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Clozapine, Antipsychotics,Other (non-Clozapine)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Lurasidone Effects on Tissue Glutamate in Schizophrenia

NCT02199743
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone, Haloperidol, Perphenazine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

NCT00868699
View directory record Official record
Conditions
Bipolar Depression
Interventions
lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
22
States / cities
Escondido, California • Garden Grove, California • Oceanside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone Pediatric Bipolar Study

NCT02046369
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Dothan, Alabama • Culver City, California • Hartford, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 2Phase 3 Interventional

NRX101 Glx Biomarker Validation Study

NCT03402152
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation
Interventions
NRX-101, Lurasidone HCl, Placebo
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Results available

Lurasidone Pediatric Pharmacokinetics Study

NCT01620060
View directory record Official record
Conditions
Schizophrenia, Autism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 20, 2026, 1:34 AM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Not applicable Interventional Results available

Biosignatures of Latuda for Bipolar Depression

NCT02239094
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lurasidone (Latuda)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

NCT00789698
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Lurasidone HC1, Quetiapine XR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
27
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

NCT01082250
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

NCT01082276
View directory record Official record
Conditions
Male, Healthy Normal Subjects
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 20, 2026, 1:34 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

NCT00868959
View directory record Official record
Conditions
Bipolar Depression
Interventions
lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
817 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
58
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 20, 2026, 1:34 AM EDT
Withdrawn Phase 4 Interventional

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

NCT01932541
View directory record Official record
Conditions
Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder, Bipolar Disorder
Interventions
Latuda (Lurasidone)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 20, 2026, 1:34 AM EDT